ABT · 10-Q · 2026Q3 · Full report

Income Tax Rate Changes

ABBOTT LABORATORIES · 2026-11-04 · Importance 42 · Surprise 40

First-nine-month 2026 taxes on earnings included approximately $540 million of expense related to a deferred tax asset recognized as a significant non-cash tax benefit in a prior year, compared with approximately $460 million in 2025. The period also included approximately $95 million of net tax expense from resolution of prior-year tax positions, compared with a $90 million net tax benefit in 2025. Excess tax benefits from share-based compensation were $28 million in 2026, versus $91 million in 2025.